A detailed history of Shell Asset Management CO transactions in Collegium Pharmaceutical, Inc stock. As of the latest transaction made, Shell Asset Management CO holds 7,367 shares of COLL stock, worth $235,007. This represents 0.01% of its overall portfolio holdings.

Number of Shares
7,367
Previous 7,652 3.72%
Holding current value
$235,007
Previous $236,000 21.19%
% of portfolio
0.01%
Previous 0.01%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

SELL
$31.23 - $40.91 $8,900 - $11,659
-285 Reduced 3.72%
7,367 $286,000
Q4 2023

Feb 14, 2024

SELL
$21.16 - $30.8 $49,239 - $71,671
-2,327 Reduced 23.32%
7,652 $236,000
Q3 2023

Nov 08, 2023

SELL
$21.23 - $24.28 $3,311 - $3,787
-156 Reduced 1.54%
9,979 $223,000
Q2 2023

Jul 28, 2023

SELL
$21.06 - $24.0 $1,179 - $1,344
-56 Reduced 0.55%
10,135 $218,000
Q1 2023

May 15, 2023

SELL
$23.0 - $29.88 $828 - $1,075
-36 Reduced 0.35%
10,191 $244,000
Q4 2022

Feb 07, 2023

SELL
$16.14 - $23.55 $33,668 - $49,125
-2,086 Reduced 16.94%
10,227 $237,000
Q3 2022

Nov 14, 2022

SELL
$15.46 - $20.1 $50,105 - $65,144
-3,241 Reduced 20.84%
12,313 $197,000
Q2 2022

Aug 09, 2022

BUY
$14.22 - $20.88 $87,040 - $127,806
6,121 Added 64.89%
15,554 $276,000
Q1 2022

May 04, 2022

SELL
$17.2 - $22.5 $23,994 - $31,387
-1,395 Reduced 12.88%
9,433 $192,000
Q4 2021

Feb 09, 2022

BUY
$17.5 - $21.35 $892 - $1,088
51 Added 0.47%
10,828 $202,000
Q3 2021

Nov 04, 2021

SELL
$17.75 - $25.39 $8,165 - $11,679
-460 Reduced 4.09%
10,777 $213,000
Q2 2021

Aug 12, 2021

BUY
$21.74 - $25.28 $153,049 - $177,971
7,040 Added 167.74%
11,237 $266,000
Q1 2021

May 10, 2021

BUY
$19.25 - $26.1 $80,792 - $109,541
4,197 New
4,197 $99,000

Others Institutions Holding COLL

About COLLEGIUM PHARMACEUTICAL, INC


  • Ticker COLL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 34,126,200
  • Market Cap $1.09B
  • Description
  • Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ...
More about COLL
Track This Portfolio

Track Shell Asset Management CO Portfolio

Follow Shell Asset Management CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Shell Asset Management CO, based on Form 13F filings with the SEC.

News

Stay updated on Shell Asset Management CO with notifications on news.